The World Health Organization (WHO) Model List of Essential Medicines for Children (EMLc) is a crucial guide for countries in prioritizing vital health products. Updated biennially, the current version, released in September 2025, marks the 10th edition.
The 2025 update includes 23 newly added medicines specifically for children. The EMLc aims to ensure access to essential treatments for childhood illnesses. It is aligned with the 24th Essential Medicines List (EML).
Key Considerations:
- Scored tablets suitable for children are considered.
- Palliative care medicines are included.
- Antiseizure medications are prioritized, including Carbamazepine, Diazepam, Lamotrigine, and others.
The EMLc guides national procurement and prioritization of medicines, promoting better health outcomes for children globally.
The World Health Organization (WHO) Model List of Essential Medicines for Children (EMLc) is a crucial guide for countries in prioritizing vital health products. Updated biennially, the current version, released in September 2025, marks the 10th edition.
The 2025 update includes 23 newly added medicines specifically for children. The EMLc aims to ensure access to essential treatments for childhood illnesses. It is aligned with the 24th Essential Medicines List (EML).
Key Considerations:
- Scored tablets suitable for children are considered.
- Palliative care medicines are included.
- Antiseizure medications are prioritized, including Carbamazepine, Diazepam, Lamotrigine, and others.
The EMLc guides national procurement and prioritization of medicines, promoting better health outcomes for children globally.
Table of contents
Importance and Impact of the EMLc
The WHO Model List of Essential Medicines for Children is more than just a list; it’s a framework for building stronger, healthier communities. Its impact resonates across various levels:
- National Policy: Governments use the EMLc to inform their national drug policies, procurement strategies, and resource allocation decisions. This helps ensure that essential medicines are available and affordable for all children.
- Healthcare Professionals: The list provides a valuable reference for doctors, nurses, and other healthcare providers, guiding them in prescribing appropriate and effective treatments.
- Pharmaceutical Industry: The EMLc can influence pharmaceutical companies’ research and development efforts, encouraging them to focus on producing essential medicines for children.
- Global Health Initiatives: The list serves as a benchmark for global health initiatives, helping to prioritize funding and support for programs aimed at improving child health.
Key Changes in the 2025 Update
While a comprehensive list of all 23 additions is beyond the scope of this article, some notable changes in the 2025 update include:
- Expanded Coverage of Infectious Diseases: The list now includes more medications for treating common childhood infections, such as pneumonia, diarrhea, and malaria.
- Improved Access to Mental Health Medications: While the 9th edition (2023) didn’t include specific psychotropic medications, the 2025 update may include revised recommendations or specific medications addressing childhood mental health needs, though details are still being finalized. It’s crucial to consult the official WHO documentation for precise details.
- Strengthened Focus on Neonatal Care: The list has been updated to include more medicines for treating newborn complications and ensuring healthy starts for infants.
Accessing the Full List and Further Information
The complete WHO Model List of Essential Medicines for Children (2025) can be accessed on the WHO website. It is recommended to consult the official document for the most accurate and up-to-date information.
This resource is invaluable for anyone involved in child health, from policymakers and healthcare professionals to researchers and advocates. By utilizing the EMLc, we can work together to ensure that all children have access to the essential medicines they need to thrive.
